Literature DB >> 21345963

Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens.

A de Rougemont1, N Ruvoen-Clouet, B Simon, M Estienney, C Elie-Caille, S Aho, P Pothier, J Le Pendu, W Boireau, G Belliot.   

Abstract

Noroviruses (NoVs) are one of the leading causes of gastroenteritis in children and adults. For the last 2 decades, genogroup II genotype 4 (GII.4) NoVs have been circulating worldwide. GII.4 NoVs can be divided into variants, and since 2002 they have circulated in the population before being replaced every 2 or 3 years, which raises questions about the role of their histo-blood group antigen (HBGA) ligands in their evolution. To shed light on these questions, we performed an analysis of the interaction between representative GII.4 variants and HBGAs, and we determined the role of selected amino acids in the binding profiles. By mutagenesis, we showed that there was a strict structural requirement for the amino acids, directly implicated in interactions with HBGAs. However, the ablation of the threonine residue at position 395 (ΔT395), an epidemiological feature of the post-2002 variants, was not deleterious to the binding of the virus-like particle (VLP) to the H antigen, while binding to A and B antigens was severely hampered. Nevertheless, the ΔT395 VLPs gained the capacity to bind to the Lewis x and sialyl-Lewis x antigens in comparison with the wild-type VLP, demonstrating that amino acid residues outside the HBGA binding site can modify the binding properties of NoVs. We also analyzed the attachment of baculovirus-expressed VLPs from six variants (Bristol, US95/96, Hunter, Yerseke, Den Haag, and Osaka) that were isolated from 1987 to 2007 to phenotyped saliva samples and synthetic HBGAs. We showed that the six variants could all attach to saliva of secretors irrespective of the ABO phenotype and to oligosaccharides characteristic of the secretor phenotype. Interestingly, Den Haag and Osaka variants additionally bound to carbohydrates present in the saliva of Lewis-positive nonsecretors. The carbohydrate binding profile and the genetic and mutagenesis analysis suggested that GII.4 binding to Lewis x and sialyl-Lewis x antigens might be a by-product of the genetic variation of the amino acids located in the vicinity of the binding site. Analysis of the binding properties for the six variants by surface plasmon resonance showed that only post-2002 variants (i.e., Hunter, Yerseke, Den Haag, and Osaka) presented strong binding to A and B antigens, suggesting that the GII.4 evolution could be related to an increased affinity for HBGAs for the post-2002 variants. The combination of increased affinity for ABH antigens and of a newly acquired ability to recognize glycans from Lewis-positive nonsecretors could have contributed to the epidemiological importance of strains such as the Den Haag GII.4 subtype.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21345963      PMCID: PMC3126233          DOI: 10.1128/JVI.02077-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein.

Authors:  X Jiang; M Wang; D Y Graham; M K Estes
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Expression of blood group-related antigens, ABH, Lewis(a), Lewis(b), Lewis(x), Lewis(y), CA19-9, and CSLEX1 in early cancer, intestinal metaplasia, and uninvolved mucosa of the stomach.

Authors:  K Murata; H Egami; Y Shibata; K Sakamoto; A Misumi; M Ogawa
Journal:  Am J Clin Pathol       Date:  1992-07       Impact factor: 2.493

Review 3.  Glycosylation features of gastric carcinoma initiation and progression. A review with emphasis on simple mucin-type carbohydrates and histo-blood group antigens of the Lewis system.

Authors:  F Carneiro; M Amado; L David; H Clausen; M Sobrinho-Simões
Journal:  Eur J Cancer Prev       Date:  1994-12       Impact factor: 2.497

4.  Sequence and expression of a candidate for the human Secretor blood group alpha(1,2)fucosyltransferase gene (FUT2). Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype.

Authors:  R J Kelly; S Rouquier; D Giorgi; G G Lennon; J B Lowe
Journal:  J Biol Chem       Date:  1995-03-03       Impact factor: 5.157

5.  Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis.

Authors:  A Z Kapikian; R G Wyatt; R Dolin; T S Thornhill; A R Kalica; R M Chanock
Journal:  J Virol       Date:  1972-11       Impact factor: 5.103

6.  Mutation in a Lordsdale norovirus epidemic strain as a potential indicator of transmission routes.

Authors:  Kate E Dingle
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

7.  Mutations within the P2 domain of norovirus capsid affect binding to human histo-blood group antigens: evidence for a binding pocket.

Authors:  Ming Tan; Pengwei Huang; Jaroslaw Meller; Weiming Zhong; Tibor Farkas; Xi Jiang
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

8.  Lewis blood group-related antigen expression in normal gastric epithelium, intestinal metaplasia, gastric adenoma, and gastric carcinoma.

Authors:  K Kobayashi; J Sakamoto; T Kito; Y Yamamura; T Koshikawa; M Fujita; T Watanabe; H Nakazato
Journal:  Am J Gastroenterol       Date:  1993-06       Impact factor: 10.864

9.  The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptors.

Authors:  Ming Tan; Rashmi S Hegde; Xi Jiang
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 10.  Norovirus gastroenteritis, carbohydrate receptors, and animal models.

Authors:  Ming Tan; Xi Jiang
Journal:  PLoS Pathog       Date:  2010-08-26       Impact factor: 6.823

View more
  73 in total

1.  Affinities of human histo-blood group antigens for norovirus capsid protein complexes.

Authors:  Ling Han; Elena N Kitova; Ming Tan; Xi Jiang; Benjamin Pluvinage; Alisdair B Boraston; John S Klassen
Journal:  Glycobiology       Date:  2014-10-01       Impact factor: 4.313

2.  Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens.

Authors:  Gabriel I Parra; Eugenio J Abente; Carlos Sandoval-Jaime; Stanislav V Sosnovtsev; Karin Bok; Kim Y Green
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

3.  Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity.

Authors:  Kari Debbink; Lisa C Lindesmith; Eric F Donaldson; Veronica Costantini; Martina Beltramello; Davide Corti; Jesica Swanstrom; Antonio Lanzavecchia; Jan Vinjé; Ralph S Baric
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

Review 4.  Norovirus.

Authors:  Elizabeth Robilotti; Stan Deresinski; Benjamin A Pinsky
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

5.  Affinities of recombinant norovirus P dimers for human blood group antigens.

Authors:  Ling Han; Pavel I Kitov; Elena N Kitova; Ming Tan; Leyi Wang; Ming Xia; Xi Jiang; John S Klassen
Journal:  Glycobiology       Date:  2012-10-30       Impact factor: 4.313

6.  Structural basis for norovirus inhibition and fucose mimicry by citrate.

Authors:  Grant S Hansman; Syed Shahzad-Ul-Hussan; Jason S McLellan; Gwo-Yu Chuang; Ivelin Georgiev; Takashi Shimoike; Kazuhiko Katayama; Carole A Bewley; Peter D Kwong
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

Review 7.  Role of plasmonics in detection of deadliest viruses: a review.

Authors:  Foozieh Sohrabi; Sajede Saeidifard; Masih Ghasemi; Tannaz Asadishad; Seyedeh Mehri Hamidi; Seyed Masoud Hosseini
Journal:  Eur Phys J Plus       Date:  2021-06-20       Impact factor: 3.911

8.  Recombination within the pandemic norovirus GII.4 lineage.

Authors:  John-Sebastian Eden; Mark M Tanaka; Maciej F Boni; William D Rawlinson; Peter A White
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

Review 9.  Epidemiology of human noroviruses and updates on vaccine development.

Authors:  Sasirekha Ramani; Robert L Atmar; Mary K Estes
Journal:  Curr Opin Gastroenterol       Date:  2014-01       Impact factor: 3.287

10.  Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.

Authors:  Kari Debbink; Lisa C Lindesmith; Eric F Donaldson; Jesica Swanstrom; Ralph S Baric
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.